Trimethaphan
Phase 1Small molecule
Trimethaphan is one of 70 small molecule programs targeting Essential Hypertension. It is currently in Phase 1.
3
Indications
8
Total Trials
2
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Edarbi
TakedaPreclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Atorvastatin Calcium
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension2 trials
Autonomic Nervous System2 trials
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trimethaphan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- VVanderbilt University